ArticleRecent advances in drug delivery and formulation2025
Formulation Development and Permeation Studies of Vancomycin Hydrochloride-Loaded Nanostructured Lipid Carrier Incorporated Thermoresponsive
Article in Recent advances in drug delivery and formulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEndophthalmitis, an inflammatory condition of the intraocular cavity, poses a significant challenge in ophthalmology due to its rapid progression and potential for vision loss. Conventional treatment modalities, such as systemic antibiotics or oral administration, often face limitations in achieving the required therapeutic levels at the target site. Hence, repeated intravitreal injections of antibiotics are currently the most preferred and recommended therapy for the management of endophthalmitis, which is an invasive technique and has certain shortcomings, elevated intraocular pressure, bleeding inside the eye, heightened likelihood of retinal detachment, retinal toxicity, and many more. Vancomycin is the first choice drug for the management of endophthalmitis and is given through intravitreal injection.
aimThe work aims to design, develop, and evaluate Vancomycin-loaded NLCs incorporated into an in-situ gel offering a new non-invasive therapeutic option for the management of Endophthalmitis.
methodsThe Vancomycin-loaded NLCs were successfully produced through a double emulsion/ solvent evaporation method employing a Box Behnken design. The optimized formulations were incorporated into an in-situ gel system by varying the concentration of Pluronic F127. The formulated gels were characterized for several parameters such as physical appearance, pH, viscosity, gelling strength, gelation temperature, in vitro release profile, and ex-vivo permeation study.
resultsThe result revealed that the formulation had a smooth appearance with a pH range from 7 to 7.5, was near the physiological pH of the eye, had content in the range of 97.5 ± 1.0 % to 99.2 ± 1.0 % and gelation temperature near body temperature. The data of release study formulation (VISG2) revealed sustained drug release compared to the control gel. The data ex vivo permeation study revealed that there was approximately a 3 folds increase in permeation of drug form (VISG2) compared to control gel (p<0.0001) and significant (2.02 folds) permeation compared to commercially available formulation (p<0.0001).
conclusionIn conclusion, the Vancomycin-loaded NLCs incorporated in-situ gel may serve as a feasible alternative to invasive intravitreal injection for the management of endophthalmitis.
Indexed as
Identifiers
39988780What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.